Effect of Macrolides on In vivo ion transport across cystic fibrosis nasal epithelium

被引:21
作者
Barker, PM
Gillie, DJ
Schechter, MS
Rubin, BK
机构
[1] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA
[2] Brown Med Sch, Providence, RI USA
[3] Wake Forest Univ, Sch Med, Dept Pediat, Winston Salem, NC 27109 USA
关键词
antibiotic; chloride; nasal potential difference; therapy;
D O I
10.1164/rccm.200311-1508OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Fourteen- and 15-member macrolide antibiotics are under investigation as potential therapeutic agents for cystic fibrosis (CF). The nonantibiotic mechanisms of action of these compounds in CF are not understood. We used nasal potential difference (NPD) measurements to test the effect of macrolides on airway epithelial ion (chloride, sodium) transport of CIF mice and humans. We tested clarithromycin and azithromycin in mice, and clarithromycin in patients with CF. Baseline and post-treatment NPD was measured in two strains (C57B16 and BalbC) of CF transmembrane regulator "knockout" and littermate control mice, and in Delta F508/Delta F508 mice. In addition, NPD was measured in 18 human subjects with CF (17 Delta F-508/Delta F-508 and 1 Delta F-508/other) who were undergoing a 12-month, randomized, double-blind crossover study of the effects of clarithromycin on pulmonary outcome in CF. Neither clarithromycin nor azithromycin affected ion transport characteristics of normal or CF nasal epithelium in either mouse or humans. We conclude that the apparent beneficial effects of macrolides on pulmonary outcome in CF are not mediated by their modulation of ion transport.
引用
收藏
页码:868 / 871
页数:4
相关论文
共 22 条
[1]   Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils [J].
Anderson, R ;
Theron, AJ ;
Feldman, C .
INFLAMMATION, 1996, 20 (06) :693-705
[2]  
[Anonymous], 2002, CROSSOVER TRIALS CLI
[3]  
Bush A, 2003, SEM RESP CRIT CARE M, V24, P737
[4]   Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial [J].
Equi, A ;
Balfour-Lynn, IM ;
Bush, A ;
Rosenthal, M .
LANCET, 2002, 360 (9338) :978-984
[5]   BIOASSAY FOR A-56268 (TE-031) AND IDENTIFICATION OF ITS MAJOR METABOLITE, 14-HYDROXY-6-O-METHYL ERYTHROMYCIN [J].
FERNANDES, PB ;
RAMER, N ;
RODE, RA ;
FREIBERG, L .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (01) :73-76
[6]  
GILLIE DJ, 2001, PEDIATR PULM, V22, P259
[7]   DIFFUSE PANBRONCHIOLITIS AND CYSTIC-FIBROSIS - EAST MEETS WEST [J].
HOIBY, N .
THORAX, 1994, 49 (06) :531-532
[8]   IN-VIVO NASAL POTENTIAL DIFFERENCE - TECHNIQUES AND PROTOCOLS FOR ASSESSING EFFICACY OF GENE-TRANSFER IN CYSTIC-FIBROSIS [J].
KNOWLES, MR ;
PARADISO, AM ;
BOUCHER, RC .
HUMAN GENE THERAPY, 1995, 6 (04) :445-455
[9]   Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides [J].
Kobayashi, H .
AMERICAN JOURNAL OF MEDICINE, 1995, 99 :S26-S30
[10]  
Labro M. T., 1998, Journal of Antimicrobial Chemotherapy, V41, P37, DOI 10.1093/jac/41.suppl_2.37